A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
Collins GP, Eyre TA, Schmitz-Rohmer D, Townsend W, Popat R, Giulino-Roth L, Fields PA, Krasniqi F, Soussain C, Stathis A, Andjelkovic N, Cunningham D, Mandic D, Radulovic S, Tijanic I, Horowitz NA, Kurtovic S, Schorb E, Schmidt C, Dimitrijević S, Dreyling M.
Collins GP, et al. Among authors: schmitz rohmer d.
Hemasphere. 2021 Oct 27;5(11):e656. doi: 10.1097/HS9.0000000000000656. eCollection 2021 Nov.
Hemasphere. 2021.
PMID: 34901759
Free PMC article.